- call +1-201-465-4211
- email sales@mrinsights.biz
Advanced renal cell carcinoma is associated with a type of kidney cancer that appears in the covering of the proximal complex tubule. The convoluted tubule is a very small part of tubes in the kidney that helps in transportation of unwanted particles from the blood to the urine. Advanced renal cell carcinoma is the most common type of kidney cancer in adults that represents nearly 2-3% of all cancer cases in adults. The disorder is asymptomatic in advanced renal cell carcinoma at initial stages that results with people often in the advanced stages of the disease by the time it is discovered. The initial symptoms of renal cell carcinoma are a general feeling of being unwell, hypertension, flank pain, weight loss, fever, blood in the urine, night sweats, and a mass in the abdomen. Management of renal cell carcinoma has seen significant development in the past few years, and new approaches are being established. Advanced renal cell carcinoma is a disease that normally cannot be treated by general therapy and is challenging to treat. Surgical removal of one or both kidneys should be considered in patients who suffer from metastatic disease before systemic therapy.
Scope of the Report:
This report studies the Advanced Renal Cell Carcinoma Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Advanced Renal Cell Carcinoma Therapeutics market by product type and applications/end industries.
Increase in aging population is one of the major factors driving the revenue growth of the renal cell carcinoma market. Furthermore, renal cell carcinoma is a rare disease with a small patient-base constitutingall ages from infants to older adults. However, the disease is predominantly noted in age group of ~ 60-70 years, exposing a higher probability of occurrence. Expanding research into orphan drugs is a factor projected to create lucrative revenue potential for drug makers of renal cell carcinoma.
Restraints include lack of technological advances in genome sequencing, stagnant number of diagnosed population base and low patient awareness levels among others.The disease pattern of renal cell carcinoma disease is also affected by the genomic alteration, changes in lifestyle etc. Other inevitable restraints include lack of product availability on specific diseases & target indications apart from feeble pipeline.
The global Advanced Renal Cell Carcinoma Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Advanced Renal Cell Carcinoma Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Acceleron Pharma
Argos Therapeutics
AVEO Pharmaceuticals
Bayer
Bristol-Myers Squibb Company
Eisai
Exelixi
Genentech
Immatics Biotechnologies
Merck
Novartis
Ono Pharmaceutical
Pfizer
Rexahn Pharmaceuticals
Hoffmann-La Roche
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Radiation Therapy
Chemotherapy
Hormone Therapy
Investigational Therapy
Market Segment by Applications, can be divided into
Hospitals
Cancer Research Institutes
Ambulatory Surgical Centers
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Advanced Renal Cell Carcinoma Therapeutics Market Overview
1.1 Product Overview and Scope of Advanced Renal Cell Carcinoma Therapeutics
1.2 Classification of Advanced Renal Cell Carcinoma Therapeutics by Types
1.2.1 Global Advanced Renal Cell Carcinoma Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Advanced Renal Cell Carcinoma Therapeutics Revenue Market Share by Types in 2017
1.2.3 Radiation Therapy
1.2.4 Chemotherapy
1.2.5 Hormone Therapy
1.2.6 Investigational Therapy
1.3 Global Advanced Renal Cell Carcinoma Therapeutics Market by Application
1.3.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Cancer Research Institutes
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Global Advanced Renal Cell Carcinoma Therapeutics Market by Regions
1.4.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Advanced Renal Cell Carcinoma Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Advanced Renal Cell Carcinoma Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Advanced Renal Cell Carcinoma Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Advanced Renal Cell Carcinoma Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Advanced Renal Cell Carcinoma Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Advanced Renal Cell Carcinoma Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Acceleron Pharma
2.1.1 Business Overview
2.1.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Acceleron Pharma Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Argos Therapeutics
2.2.1 Business Overview
2.2.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Argos Therapeutics Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 AVEO Pharmaceuticals
2.3.1 Business Overview
2.3.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 AVEO Pharmaceuticals Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Bayer
2.4.1 Business Overview
2.4.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Bayer Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bristol-Myers Squibb Company
2.5.1 Business Overview
2.5.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Bristol-Myers Squibb Company Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Eisai
2.6.1 Business Overview
2.6.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Eisai Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Exelixi
2.7.1 Business Overview
2.7.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Exelixi Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 Genentech
2.8.1 Business Overview
2.8.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Genentech Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 Immatics Biotechnologies
2.9.1 Business Overview
2.9.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Immatics Biotechnologies Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 Merck
2.10.1 Business Overview
2.10.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Merck Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.11 Novartis
2.11.1 Business Overview
2.11.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Novartis Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.12 Ono Pharmaceutical
2.12.1 Business Overview
2.12.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Ono Pharmaceutical Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.13 Pfizer
2.13.1 Business Overview
2.13.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Pfizer Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.14 Rexahn Pharmaceuticals
2.14.1 Business Overview
2.14.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Rexahn Pharmaceuticals Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.15 Hoffmann-La Roche
2.15.1 Business Overview
2.15.2 Advanced Renal Cell Carcinoma Therapeutics Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Hoffmann-La Roche Advanced Renal Cell Carcinoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Advanced Renal Cell Carcinoma Therapeutics Market Competition, by Players
3.1 Global Advanced Renal Cell Carcinoma Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Advanced Renal Cell Carcinoma Therapeutics Players Market Share
3.2.2 Top 10 Advanced Renal Cell Carcinoma Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Advanced Renal Cell Carcinoma Therapeutics Market Size by Regions
4.1 Global Advanced Renal Cell Carcinoma Therapeutics Revenue and Market Share by Regions
4.2 North America Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Advanced Renal Cell Carcinoma Therapeutics Revenue by Countries
5.1 North America Advanced Renal Cell Carcinoma Therapeutics Revenue by Countries (2013-2018)
5.2 USA Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Advanced Renal Cell Carcinoma Therapeutics Revenue by Countries
6.1 Europe Advanced Renal Cell Carcinoma Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Advanced Renal Cell Carcinoma Therapeutics Revenue by Countries
7.1 Asia-Pacific Advanced Renal Cell Carcinoma Therapeutics Revenue by Countries (2013-2018)
7.2 China Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Advanced Renal Cell Carcinoma Therapeutics Revenue by Countries
8.1 South America Advanced Renal Cell Carcinoma Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Advanced Renal Cell Carcinoma Therapeutics by Countries
9.1 Middle East and Africa Advanced Renal Cell Carcinoma Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Advanced Renal Cell Carcinoma Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Advanced Renal Cell Carcinoma Therapeutics Market Segment by Type
10.1 Global Advanced Renal Cell Carcinoma Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Advanced Renal Cell Carcinoma Therapeutics Market Forecast by Type (2018-2023)
10.3 Radiation Therapy Revenue Growth Rate (2013-2023)
10.4 Chemotherapy Revenue Growth Rate (2013-2023)
10.5 Hormone Therapy Revenue Growth Rate (2013-2023)
10.6 Investigational Therapy Revenue Growth Rate (2013-2023)
11 Global Advanced Renal Cell Carcinoma Therapeutics Market Segment by Application
11.1 Global Advanced Renal Cell Carcinoma Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Advanced Renal Cell Carcinoma Therapeutics Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Cancer Research Institutes Revenue Growth (2013-2018)
11.5 Ambulatory Surgical Centers Revenue Growth (2013-2018)
11.6 Others Revenue Growth (2013-2018)
12 Global Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast (2018-2023)
12.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast (2018-2023)
12.2 Global Advanced Renal Cell Carcinoma Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Advanced Renal Cell Carcinoma Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Advanced Renal Cell Carcinoma Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Advanced Renal Cell Carcinoma Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Advanced Renal Cell Carcinoma Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Advanced Renal Cell Carcinoma Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Advanced Renal Cell Carcinoma Therapeutics Picture
Table Product Specifications of Advanced Renal Cell Carcinoma Therapeutics
Table Global Advanced Renal Cell Carcin
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
